烟台正海生物科技股份有限公司 2023 年年度股东大会决议公告 股东大会决议公告 证券代码：300653 证券简称：正海生物 公告编号：2024-026 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 烟台正海生物科技股份有限公司（以下简称"公司"）2023 年年度股东大会 于 2024 年 4 月 22 日下午 14:30 在烟台经济技术开发区南京大街 7 号烟台正海生 物科技股份有限公司会议室召开，本次会议采取现场投票与网络投票结合的表决 方式。其中： （1）现场会议召开时间：2024 年 4 月 22 日（星期一）下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 4 月 22 日的交易时间，即 9:15—9:25，9:30—11:30 和 13:00—15:00；通 过深圳证券交易所互联网系统投票的具体时间为2024年4月22日9:15—15:00。 本次股东大会由公司董事会召集，董 ...

监事会完成换届选举的公告 证券代码：300653 证券简称：正海生物 公告编号：2024-028 烟台正海生物科技股份有限公司 关于监事会完成换届选举的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 烟台正海生物科技股份有限公司（以下称"公司"）于 2024 年 4 月 22 日召 开了 2023 年年度股东大会，审议通过了《关于公司监事会换届选举暨选举第四 届监事会非职工代表监事的议案》，同意选举许月莉女士、潘励山先生 2 人为公 司第四届监事会非职工代表监事，与公司职工代表大会选举产生的职工代表监事 宋广平先生共同组成公司第四届监事会，任期自本次股东大会审议通过之日起三 年。上述人员简历详见公司于 2024 年 4 月 2 日在巨潮资讯网（www.cninfo.com.cn） 披露的《关于监事会换届选举的公告》和《关于选举职工代表监事的公告》。 上述人员任职资格均符合担任上市公司监事的条件，能够胜任所聘岗位职责 的要求，不存在《公司法》、《深圳证券交易所上市公司自律监管指引第 2 号—创 业板上市公司规范运作》等规范性文件以及《公司章程》中规定不得担 ...

山东川奇律师事务所 关于烟台正海生物科技股份有限公司 2023 年年度股东大会的 法律意见书 致：烟台正海生物科技股份有限公司 山东川奇律师事务所（以下简称"本所"）接受烟台正海生物科 技股份有限公司（以下简称"公司"）的委托，指派王建洲律师、徐 学广律师（以下合称"本所律师"）列席并见证公司 2023 年度股东 大会（下称"本次股东大会"）。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》、《上市公司股东大会规则》（以下简称"《股东大 会规则》"）等法律、行政法规及公司《章程》的有关规定，本所律师 按照中国律师行业公认的业务标准、道德规范和勤勉尽责精神，对本 次股东大会的有关事项进行了核查和验证，出具法律意见书。 在本法律意见书中，本所律师根据《股东大会规则》的要求，就 本次股东大会的召集人资格、召集、召开程序是否合法及是否符合公 司《章程》、出席会议人员资格的合法有效性、会议表决程序、表决 方式的合法有效性发表意见。 本所在此同意贵公司将本法律意见书作为本次股东大会的必备 文件予以公告，并依法对本所出具的法律意见书承担责任。 一、本次股东大会的召集人资格及召集、召开程序 ...

股东大会提示性公告 证券代码：300653 证券简称：正海生物 公告编号：2024-025 烟台正海生物科技股份有限公司 关于召开 2023 年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 经烟台正海生物科技股份有限公司（以下简称"公司"）第三届董事会第十 五次会议审议通过，决定于 2024 年 4 月 22 日（星期一）召开 2023 年年度股东 大会。公司已于 2024 年 4 月 2 日在巨潮资讯网（www.cninfo.com.cn）上披露了 《关于召开 2023 年年度股东大会的通知》（公告编号 2024-019），本次股东大会 采用现场投票和网络投票相结合的方式召开，现将本次股东大会的有关事宜再次 提示如下： 一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会 2、召集人：公司董事会 3、会议召开的合法、合规性：公司第三届董事会第十五次会议审议通过， 决定召开 2023 年年度股东大会，召集程序符合有关法律、行政法规、部门规章、 规范性文件和公司章程的规定。 4、会议召开的日期、时间： （1）现场会议召开 ...

关于首次回购公司股份的公告 证券代码：300653 证券简称：正海生物 公告编号：2024-024 烟台正海生物科技股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 烟台正海生物科技股份有限公司（以下简称"公司"）于 2023 年 12 月 20 日召开第 三届董事会第十四次会议、第三届监事会第十二次会议审议通过了《关于回购公司股份 方案的议案》，同意公司使用自有资金以集中竞价交易方式回购部分公司已发行的人民 币普通股（A 股）股份，用于实施股权激励或员工持股计划。本次回购资金总额不低于 人民币 2,500 万元（含）且不超过人民币 5,000 万元（含），回购价格不超过人民币 44.90 元/股（含）。具体内容详见公司于 2023 年 12 月 20 日在巨潮资讯网（www.cninfo.com.cn） 披露的《关于回购公司股份方案的公告》（公告编号：2023-072）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号— —回购股份》的规定，公司应当在首次回购股份事实发生的次一交易日予以披露 ...

关于公司取得医疗器械注册证的公告 本产品光固化复合树脂，为前后牙通用型复合树脂，具有良好的操作便利性 和机械性能，能够满足临床需求，将进一步丰富公司口腔领域产品管线。 三、风险提示 烟台正海生物科技股份有限公司 关于公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 烟台正海生物科技股份有限公司（以下简称"公司"）于近日取得国家药品 监督管理局下发的《中华人民共和国医疗器械注册证》，现将相关情况公告如下： 一、该医疗器械的基本信息 | 光固化复合 | 国械注准 | 年 2029 3 | 至 | 月 | 日 28 | 第三类 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 树脂 | 20243170630 | | | | | 医疗器械 | | | 产品名称 | 注册证编号 | 注册证有效期 | | | | 注册分类 | 适用范围 该产品用于前后牙直接修 复，堆核制作，夹板、间接 修复（包括嵌体、高嵌体） | 二、对公司的影响 证券代码：300653 证券简称：正海生物 公告 ...

关于回购股份的进展公告 烟台正海生物科技股份有限公司 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 烟台正海生物科技股份有限公司（以下简称"公司"）于 2023 年 12 月 20 日召开第 三届董事会第十四次会议、第三届监事会第十二次会议审议通过了《关于回购公司股份 方案的议案》，同意公司使用自有资金以集中竞价交易方式回购部分公司已发行的人民 币普通股（A 股）股份，用于实施股权激励或员工持股计划。本次回购资金总额不低于 人民币 2,500 万元（含）且不超过人民币 5,000 万元（含），回购价格不超过人民币 44.90 元/股（含）。按照回购价格上限和回购金额上限测算，预计可回购股份数量为 1,113,586 股，约占公司总股本的 0.62%。按照回购价格上限和回购金额下限测算，预计可回购股 份数量为 556,793 股，约占公司总股本的 0.31%。具体回购股份数量以回购实施完成时 实际回购的股份数量为准。本次回购股份的实施期限为自公司董事会审议通过本次回购 股份方案之日起 12 个月内。具体内容详见公司分别于 2023 年 ...

Revenue and Financial Performance - The company's operating revenue for 2023 was ¥413,652,710.67, a decrease of 4.52% compared to ¥433,224,730.58 in 2022[26]. - Net profit attributable to shareholders increased by 2.98% to ¥190,957,573.45 in 2023 from ¥185,436,805.06 in 2022[26]. - The basic earnings per share decreased by 17.19% to ¥1.06 in 2023, down from ¥1.28 in 2022[26]. - Total assets increased by 6.78% to ¥1,053,824,628.67 at the end of 2023, compared to ¥986,904,775.50 at the end of 2022[26]. - The company reported a net cash flow from operating activities of ¥180,477,813.36, a decrease of 3.92% from ¥187,838,040.27 in 2022[26]. - The total amount of non-recurring gains and losses for 2023 was ¥23,030,710.20, an increase from ¥12,828,645.65 in 2022[32]. - The company achieved quarterly revenues of ¥109,080,515.27, ¥115,425,055.33, ¥97,275,956.97, and ¥91,871,183.10 across the four quarters of 2023[28]. - The company’s net profit attributable to shareholders for the fourth quarter was ¥42,622,352.21, showing a decline compared to previous quarters[28]. - The company has a profit distribution plan approved by the board to distribute a cash dividend of 8.00 RMB per 10 shares (including tax) to all shareholders, based on 180,000,000 shares[6]. - The company distributed a cash dividend of RMB 6.00 per 10 shares for the year 2022, totaling RMB 108 million, completed on May 30, 2023[153]. - For the year 2023, the company plans to distribute a cash dividend of RMB 8.00 per 10 shares, totaling RMB 144 million[155]. Product Development and Innovation - The company emphasizes the risks associated with new product development, which involves a lengthy and complex process from laboratory research to market approval[6]. - The company is committed to continuous innovation in regenerative medicine, leveraging its technological advantages to maintain a leading position in the industry[110]. - The company is currently in the clinical stage for several new products, including breast patches and oral cavity products, indicating ongoing innovation and development efforts[111]. - The company has completed clinical trials for its calcium silicate bioceramic bone repair material, which is the first of its kind in China, and is currently in the statistical analysis phase[53]. - The company has obtained medical device registration certificates for new products including phosphoric acid etchant and dental fissure sealant, expanding its product line in the oral field[52]. - The company continues to innovate with a product development strategy that includes sales, registration, clinical use, and research, ensuring sustainable competitive advantages[52]. - The absorbable dura mater patch and skin repair membrane have completed renewal registrations, ensuring ongoing production and sales[52]. Market Position and Strategy - The company operates in the regenerative medicine sector, focusing on innovative products to meet clinical needs[35]. - The company is actively pursuing market expansion and innovation in regenerative medicine, aiming to strengthen its market position and adapt to industry trends[41]. - The company has a strong brand influence and positive reputation in clinical applications, contributing to its market recognition[4]. - The company has established a distribution network of over 1,140 dealers, ensuring extensive market coverage across all provinces in China[62]. - The company has successfully participated in centralized procurement in 12 provinces and regions led by Liaoning and 6 provinces led by Shaanxi, maintaining a record of winning all bids in these regions[48]. - The company aims to strengthen its position in the regenerative medicine sector, focusing on innovative products and technologies such as signaling molecules, seed cells, and synthetic biology[99]. - The company anticipates potential impacts from centralized procurement policies on its product sales, particularly in the brain membrane product line[111]. Risk Management - The company is actively addressing risks related to product quality, industry policy changes, and external environmental factors[6]. - The company faces growth risks due to its reliance on key products, which have seen rapid growth but may be impacted by market changes and procurement policies[104]. - The company is also exposed to risks related to new product development and registration, which involve complex and lengthy processes[105]. - The concentration of its main products in the regenerative medicine field poses a risk if market conditions or demand significantly change[106]. - The company must navigate risks associated with industry policies and external environmental changes, particularly regarding high-value medical consumables procurement[107]. Governance and Management - The company has established a governance structure that separates powers among the shareholders' meeting, board of directors, and supervisory board[117]. - The board of directors consists of 9 members, including 3 independent directors, meeting legal requirements for composition[118]. - The company has a dedicated committee for salary and performance evaluation, ensuring that executive compensation aligns with performance[120]. - The company has established a performance evaluation system for its executives, ensuring transparency and compliance with legal regulations[120]. - The company has implemented a comprehensive salary management system that includes basic salary, performance pay, allowances, and bonuses, aiming to enhance employee motivation and satisfaction[144]. - The company has committed to transparent information disclosure, utilizing multiple platforms to ensure equal access for all shareholders[120]. - The company has established a robust internal control system to ensure compliance and effective risk management, enhancing operational efficiency[156]. Environmental and Social Responsibility - The company has implemented various environmental protection measures, including the installation of activated carbon adsorption boxes and low-nitrogen combustion technology[161]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[162]. - The company conducts quarterly inspections of its pollutant discharge by qualified third-party testing agencies[162]. - The company has established a comprehensive internal control system for environmental protection in compliance with national regulations[161]. - The company has committed to optimizing production processes to reduce waste emissions and meet environmental standards[161]. Shareholder Information - The total number of shares remains at 180,000,000, with no changes in shareholding structure or issuance of new shares[192][193]. - Major shareholder, Mibohai, holds 33.87% of shares, totaling 60,961,500 shares, with a pledge of 16,000,000 shares[195]. - Longwood Biotechnologies Inc. holds 7.67% of shares, totaling 13,811,874 shares, with a decrease of 680,000 shares during the reporting period[195]. - The company has a total of 2,884,200 shares held by Huaxia Life Insurance, representing 1.60% of shares[195]. - The top ten shareholders include various institutional investors, with the largest being Mibohai and Longwood Biotechnologies Inc.[196]. - The total number of shares held by the top ten unrestricted shareholders is 83,000,000 shares[196]. - The company has not reported any changes in the top ten shareholders compared to the previous period[198].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - In 2023, the company achieved revenue of 413.65 million yuan, a decrease of 4.52% year-on-year, and a net profit attributable to shareholders of 190.96 million yuan, an increase of 2.98% year-on-year, which was below expectations [2] - The company's brain membrane products showed steady growth, with revenue reaching 165 million yuan, an increase of 5.87% year-on-year, and successful participation in centralized procurement in multiple provinces [2][3] - The active biological bone product has completed production verification and is expected to contribute to revenue growth in 2024, with over two-thirds of provinces having completed the registration process [3] - The oral repair membrane and bone repair materials are anticipated to accelerate sales due to the implementation of centralized procurement policies in the dental implant sector, despite a decline in revenue for these products in 2023 [4] - The profit forecast for 2024-2025 has been adjusted, with net profit estimates of 226.31 million yuan and 274.62 million yuan respectively, corresponding to a P/E ratio of 19 and 16 times [4] Financial Summary - Total revenue is projected to increase from 413.65 million yuan in 2023 to 490.90 million yuan in 2024, with a year-on-year growth rate of 18.67% [1][4] - Net profit attributable to shareholders is expected to grow from 190.96 million yuan in 2023 to 226.31 million yuan in 2024, reflecting an 18.51% increase [1][4] - The latest diluted EPS is forecasted to rise from 1.06 yuan in 2023 to 1.26 yuan in 2024 [1][4]

股东大会通知 证券代码：300653 证券简称：正海生物 公告编号：2024-019 烟台正海生物科技股份有限公司 关于召开 2023 年年度股东大会的通知 一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会 2、召集人：公司董事会 3、会议召开的合法、合规性：公司第三届董事会第十五次会议审议通过， 决定召开 2023 年年度股东大会，召集程序符合有关法律、行政法规、部门规章、 规范性文件和公司章程的规定。 4、会议召开的日期、时间： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《烟台正海生物科技股份有限公司章程》（以下简称"《公司章程》"）有 关规定，经烟台正海生物科技股份有限公司（以下简称"公司"）第三届董事会 第十五次会议审议通过，决定于 2024 年 4 月 22 日（星期一）召开 2023 年年度 股东大会，现将会议相关事项通知如下： （1）现场会议召开时间：2024 年 4 月 22 日（星期一）14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 4 月 22 日的交易时间，即 9: ...